Paper36652154
Impact of silencing eEF2K expression on the malignant properties of chordoma.
Aydemir E and 5 others. Mol Biol Rep, 2023. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Impact of silencing eEF2K expression on the malignant properties of chordoma. Papers, record 36652154. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36652154
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Elongation Factor 2 Kinase | Major topic |
| Chordoma | Major topic |
| Humans | |
| Phosphorylation | |
| Cell Line | |
| Signal Transduction |
Source PubMed
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21531565 | The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. | Trends Biochem Sci | 2011 | https://conductscience.org/library/papers/21531565 | PubMed |
| 2 | 23182879 | Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells. | Autophagy | 2013 | https://conductscience.org/library/papers/23182879 | PubMed |
| 3 | 2390990 | Functional properties of phosphorylated elongation factor 2. | Eur J Biochem | 1990 | https://conductscience.org/library/papers/2390990 | PubMed |
| 4 | 28060762 | Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC. | Oncotarget | 2017 | https://conductscience.org/library/papers/28060762 | PubMed |
| 5 | 34532346 | Insights Into the Pathologic Roles and Regulation of Eukaryotic Elongation Factor-2 Kinase. | Front Mol Biosci | 2021 | https://conductscience.org/library/papers/34532346 | PubMed |
| 6 | 29050305 | Calyxin Y sensitizes cisplatin-sensitive and resistant hepatocellular carcinoma cells to cisplatin through apoptotic and autophagic cell death via SCF βTrCP-mediated eEF2K degradation. | Oncotarget | 2017 | https://conductscience.org/library/papers/29050305 | PubMed |
| 7 | 34352439 | eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients. | Pathol Res Pract | 2021 | https://conductscience.org/library/papers/34352439 | PubMed |
| 8 | 35026050 | Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. | Cancer | 2022 | https://conductscience.org/library/papers/35026050 | PubMed |
| 9 | 2662114 | Chordoma: a critical review of diagnosis and treatment. | Orthop Clin North Am | 1989 | https://conductscience.org/library/papers/2662114 | PubMed |
| 10 | 19570961 | Response to imatinib plus sirolimus in advanced chordoma. | Ann Oncol | 2009 | https://conductscience.org/library/papers/19570961 | PubMed |
| 11 | 19401700 | Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. | Br J Cancer | 2009 | https://conductscience.org/library/papers/19401700 | PubMed |
| 12 | 30268477 | Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. | Lung Cancer | 2018 | https://conductscience.org/library/papers/30268477 | PubMed |
| 13 | 25464034 | Stress-mediated translational control in cancer cells. | Biochim Biophys Acta | 2015 | https://conductscience.org/library/papers/25464034 | PubMed |
| 14 | 26806303 | Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases. | Acta Pharmacol Sin | 2016 | https://conductscience.org/library/papers/26806303 | PubMed |
| 15 | 22911754 | Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. | PLoS One | 2012 | https://conductscience.org/library/papers/22911754 | PubMed |
| 16 | 11227920 | Chordoma: incidence and survival patterns in the United States, 1973-1995. | Cancer Causes Control | 2001 | https://conductscience.org/library/papers/11227920 | PubMed |
| 17 | 22002331 | Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. | Int J Oncol | 2012 | https://conductscience.org/library/papers/22002331 | PubMed |
| 18 | 30814891 | The effect of TWIST silencing in metastatic chordoma cells. | Turk J Biol | 2018 | https://conductscience.org/library/papers/30814891 | PubMed |
| 19 | 27756261 | Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways. | BMC Cancer | 2016 | https://conductscience.org/library/papers/27756261 | PubMed |
| 20 | 25666164 | Preclinical and clinical development of siRNA-based therapeutics. | Adv Drug Deliv Rev | 2015 | https://conductscience.org/library/papers/25666164 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 39738914 | Combinatorial therapies for epigenetic, immunotherapeutic, and genetic targeting of chordoma. | J Neurooncol | 2025 | https://conductscience.org/library/papers/39738914 |
Source PubMed
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EEF2 | 1938 | PubTator's text mining | https://conductscience.org/library/genes/1938 | NCBI Gene |
| EEF2K | 29904 | PubTator's text mining | https://conductscience.org/library/genes/29904 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36652154
GET https://conductscience.org/api/papers/v1/36652154/references?page=2